CONNECT BIOPHARMA HOLDINGS L (CNTB)

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the...

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from...

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the...

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO,...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

Connect Biopharma stock gains on asthma data (NASDAQ:CNTB)

Connect Biopharma (CNTB) shares surge 24% in premarket trading after its lead product candidate for asthma reaches main goal in Phase 2b trial. Read more here.

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant...

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the...

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...

Connect and Simcere sign license agreement for autoimmune drug Rademikibart (NASDAQ:CNTB)

Connect Biopharma (CNTB) said Simcere Pharmaceutical and Connect Biopharma HongKong entered into an exclusive license and collaboration agreement in relation to

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

Connect Biopharma stock rises on positive data from dermatitis mAb (NASDAQ:CNTB)

Connect Biopharma's shares surge 28% as it reports positive long-term data from a trial of its rademikibart drug candidate for atopic dermatitis.

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater ChinaConnect Biopharma...

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and...

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the...